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Vascular permeability factor (VPF) is a highly conserved 34-42-kD protein secreted by many tumor cells. Among the most potent vascular permeability-enhancing factors known, VPF is also a selective vascular endothelial cell mitogen, and therefore has been called vascular endothelial cell growth factor (VEGF). Our goal was to define the cellular sites of VPF (VEGF) synthesis and accumulation in tumors in vivo. Immunohistochemical studies were performed on solid and asdtes guinea pig line 1 and line 10 bile duct carcinomas using antibodies directed against peptides synthesized to represent the NH2-terminal and internal sequences of VPF. These antibodies stained tumor cells and, uniformly and most intensely, the endothelium of immediately adjacent blood vessels, both preexisting and those newly induced by tumor angiogenesis. A similar pattern of VPF staining was observed in autochthonous human lymphoma. In situ hybridization demonstrated VPF mRNA in nearly all line 10 tumor cells but not in tumor blood vessels, indicating that immunohistochemical labeling of tumor vessels with antibodies to VPF peptides reflects uptake of VPF, not endogenous synthesis. VPF protein staining was evident in adjacent preexisting venules and small veins as early as 5 h after tumor transplant and plateaued at maximally intense levels in newly induced tumor vessels by -5 d. VPF-stained vessels were also hyperpermeable to macromolecules as judged by their capacity to accumulate circulating colloidal carbon. In contrast, vessels more than "~0.5 mm distant from tumors were not hyperpermeable and did not exhibit immunohistochemical staining for VPF. Vessel staining disappeared within 24-48 h of tumor rejection. These studies indicate that VPF is synthesized by tumor cells in vivo and accumulates in nearby blood vessels, its target of action. Because leaky tumor vessels initiate a cascade of events, which include plasma extravasation and which lead ultimately to angiogenesis and tumor stroma formation, VPF may have a pivotal role in promoting tumor growth. Also, VPF immunostaining provides a new marker for tumor blood vessels that may be exploitable for tumor imaging or therapy. V ascular permeability factor (VPF) is thought to be responsible for the vascular hyperpermeability and consequent plasma protein-rich fluid accumulation that occurs in solid and ascites tumors (1) (2) (3) . In addition, VPF exerts a number of other effects on vascular endothelial cells (EC); e.g., VPF increases intracelhlar caldum, stimulates inositol triphosphate formation, provokes yon Willebrand factor release, and stimulates tissue factor expression (4, 5) . VPF is also a specific EC mitogen and has been alternatively called vascular endothelial cell growth factor (VEGF) (6) (7) (8) (9) .
In the present study, we used in situ hybridization and immunohistochemistry to define the distribution of VPF in tumors in vivo. Not unexpectedly, abundant VPF mRNA and protein were present in tumor cells. Of great interest, however, staining for VPF protein was selectively concentrated in tumor-associated blood vessels, the putative target of VPF action in angiogenesis and tumor stroma generation.
Materials and Methods
Animals, Tumors, and An@eptide Antibodies. Ascites variants of chemically induced guinea pig line 1 and line 10 bile duct carcinomas were passaged in the peritoneal cavities of inbred strain 2 guinea pigs (1). To form solid tumors, 3 x 10 6 washed ascites tumor cells were injected subcutaneously into 400 g strain 2 guinea pigs (1). To identify leaky blood vessels, colloidal carbon was injected intravenously 30 min before tumor harvest (10) . Autochthonous human tumors were obtained after surgery.
The NH2-terminal 25-amino acid sequence of guinea pig VPF, here designated peptide 1A and expressed in single letter code, is APMAEGEQKPREVVKFMDVYKRSYC (11) . The 26-amino acid NH2 terminus of human VPF (peptide 1B) differs from that of guinea pig VPF by the six underlined amino acids: AP-MAEGGGQNHHEVVKFMDVYQRSYC (8) . These and an internal peptide (CECILPKKDRARQEKKSVR, peptide 6) corresponding to amino acids 102-119 of the 189-amino acid form of human VPF (8) were synthesized, coupled to a protein carrier, and used to immunize rabbits (11) .
Immunohistockemistry and ln Situ Hybridization. Guinea pig tissues were fixed in formalin or carbodiimide and embedded in paraffin. Fresh frozen sections of human tumors were fixed in acetone, lmmunohistochemistry was performed on 5-7/~m paraffin or frozen sections, using affinity-purified first antibodies to guinea pig or human VPF peptides and an avidin-biotin peroxidase procedure. Controls included substitution of the first antibody with an unrelated rabbit antipeptide antibody, preabsorption of first antibody with specific peptide, and on-the-slide competition for first antibody with specific peptide.
In situ hybridization was performed using 3sS-labeled singlestranded RNA probes prepared by in vitro transcription of a 204-bp guinea pig VPF cDNA fragment cloned in pGem3Zf(+) (12; B. Berse et al., manuscript submitted for publication). The most striking finding was that the new blood vessels induced by both line 1 and line 10 tumors stained consistently and intensdy with antibodies to VPF peptides 1A and 6 (Fig. 1) . Vessd staining was circumferential and involved EC and vascular basement membranes; sometimes, adjacent extracellular matrix also stained weakly (Fig. 1, A and D) . Line 1 tumors underwent ceU-mediated immune rejection (3) which was accompanied by a striking and rapid (within 24--48 h) loss of vessd staining (not shown). The rapid depletion of VPF that accompanied tumor destruction suggests rapid turnover of blood vessel-associated VPF. Preliminary studies with antibodies to VPF peptide l_B indicate that human tumors also exhibit VPF staining and in a pattern similar to that of guinea pig tumors (Fig. 1 G) .
Results and Discussion

Localization of VPF (VEGF) in Tumors by
In addition to the tumor microvasculature, vessds coursing through immediately adjacent normal tissues also exhibited specific antibody staining (Fig. 1 F) . Immunoreactive vessels were venules and small veins within m0.5 mm of tumors; arterioles, capillaries, and vessels of any type at greater distances from tumor or in other tissues and organs exhibited no staining. Consistent with these findings, antibodies to VPF peptide 1A also stained immediately adjacent, preexisting host venules and small veins as early as 5 h after tumor cell transplant. These preexisting blood vessels, as well as induced tumor vessels, were hyperpermeable as judged by their concentration of circulating colloidal carbon (10) .
A minority of tumor cells stained with antibody to VPF peptide 1A, but nearly all stained with the antibody to peptide 6 (Fig. 1, A , B~ and/4), suggesting that VPF is abundantly present in nearly all tumor cells. The poor tumor cell staining with antipeptide 1A probably represents failure of fixation to preserve cytoplasmic VPF in a conformation accessible to this antibody. Using in situ hybridization (Fig.  2) , nearly all line 10 solid or ascites tumor cells reacted with the antisense RNA probe for guinea pig VPF mRNA; however, tumor blood vessels were negative for VPF transcript.
Relation of VPF (VEGF) Synthesis and Accumulation to Tumor
Stroma Generation. Our data clearly indicate that VPF is abundantly synthesized by tumor cells but not detectably by EC; therefore, the VPF identified in tumor-associated vessds reflects selective binding of tumor cell-secreted VPF. We did not unequivocally identify the precise vascular structures to which tumor cell-secreted VPF bound. EC have receptors for VPF (4, 13, 14) , and it is likely that some of the staining represents VPF that has bound to the EC surface or that has been subsequently internalized. However, VPF also binds to heparin (2) , and some of the staining may reflect binding of VPF to heparin-like proteoglycans present either in the vascular basement membrane or associated with EC. Indeed, cell surface heparin-like molecules are required for binding bFGF, another growth factor implicated in angiogenesis, to its high affinity receptor (15) .
The intense tumor vessel labeling observed with anti-VPF peptide antibodies was unexpected. VPF exerts its effects on vascular endothelium at low nM to sub-pM concentrations, well below those detectable by immunohistochemistry; e.g., staining could not be demonstrated when VPF was injected into normal guinea pig skin in amounts that greatly increased local vascular hyperpermeability. Therefore, VPF accumulates in tumor blood vessels in amounts much greater than those necessary to trigger vascular responses. Tumor vessel binding may provide a mechanism for retaining and concentrating VPF, thereby maximizing its activity locaUy while preventing its spread to more distal sites.
Taken together, our data support a model of tumor stroma generation that is initiated by tumor cell secretion of VPF (1, 3) . VPF acts directly on EC, initially to induce vascular hyperpermeability and later to maintain hyperpermeability and to promote endothelial cell growth, perhaps in concert with other growth factors such as bFGF (16) . Tumor vessel hyperpermeability results in extravasation and clotting of fibrinogen to form an extravascular fibrin gel that provides a favorable substrate for invasion by fibroblasts and EC (3, 10) ; together, these transform the fibrin gel into granulation tissue and, later, into desmoplastic scar. Fibrin gds alone can replicate this entire response without the need for tumor cells or exogenous growth factors (3). Thus, with its dual actions on EC permeability and proliferation, VPF initiates and perpetuates a chain of events that produces tumor stroma by a process analogous to normal wound healing (3). Finally, it should be noted that VPF immunostaining distinguishes tumor blood vessels from those found elsewhere in tumor-bearing or control animals. This finding stands in contrast to the widespread distribution of bFGF in vascular basement membranes of normal tissues (17) . VPF provides a new marker for tumor blood vessels and may offer a useful target for tumor imaging and therapy. 
